Integrating KMT2A-PTD into DNA NGS to Predict Outcomes in AML, MDS
Integrating the assessment of KMT2A-PTD into standard DNA sequencing may be prognostically valuable for patients with MDS or AML.
All articles by John Eckman
Several Factors May Predict Risk of ILD/Pneumonitis After Trastuzumab Deruxtecan
The risk of ILD/pneumonitis was associated with patient age, time since cancer diagnosis, dose of trastuzumab deruxtecan, and other factors.
Incidence of Distant-Stage Cervical Cancer Increasing in the US
The incidence of distant-stage cervical cancer in the United States increased by 1.3% per year from 2001 to 2018.
Gefitinib Plus Chemo Improves PFS2 Over Gefitinib Alone in EGFR-Mutant NSCLC
Patients who received gefitinib plus platinum chemotherapy had significantly longer PFS2 than patients who received gefitinib alone.
Normonatremia Tied to Outcomes in Metastatic Renal Cell Carcinoma
Serum sodium levels in the lower end of the normal range are associated with inferior outcomes in metastatic renal cell carcinoma, a study suggests.
Pola-R-CHP May Be Cost Effective, Depending on PFS Outcomes in Previously Untreated DLBCL
Researchers sought to determine whether combination pola-R-CHP would be cost-effective for patients with previously untreated DLBCL.
BMP4 Expression Levels May Predict Clinical Outcomes in Pediatric BCP-ALL
BMP4 could be a therapeutic target in B-cell precursor acute lymphoblastic leukemia.
Teclistamab Shows Promising Efficacy in Multiple Myeloma
Teclistamab yields deep and durable responses in patients with multiple myeloma, according to researchers.
RNA Sequencing Reveals Clinically Relevant Alterations in Pediatric Low-Grade Glioma
RNA sequencing confirmed the alterations most frequently described in low-grade glioma and revealed rare gene fusions.
Molecular Analysis Refines Diagnosis, Enables Personalized Treatment for Pediatric CNS Tumors
Of the patients who completed follow-up, 60% had a targeted therapy recommendation.
- Loading...
Loading...
Next post in ISPNO 2022
Loading... 
Loading...